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Abstract: Funding for biomedical and neuroscience research
has increased over the last decade but without a concomi-
tant increase in new therapies. This study’s objectives were
to determine the level and principal sources of recent fund-
ing for Parkinson disease (PD) research and to determine
the current state of PD drug development. We determined
the level and principal sources of recent funding for PD
research from the following sources: US federal agencies,
large PD foundations based in the United States, and global
industry. We assessed the status of PD drug development
through the use of a proprietary drug pipeline database.
Funding for PD research from the sources examined was
approximately $1.1 billion in 2003 and $1.2 billion in 2005.
Industry accounted for 77% of support from 2003 to 2005.
The number of drugs in development for PD increased from
67 in 2003 to 97 in 2007. Of the companies with at least
one compound in development for PD in 2007, most were
small (62% had annual revenue of less than $100 million),
and most (53%) were based outside the United States. These
companies will likely require partnerships to drive success-
ful development of new PD therapies.  2009 Movement
Disorder Society
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Funding for biomedical research as a whole has
grown dramatically over the past decade.1,2 Within
neurosciences, funding increased from $4.8 billion in
1995 to $14.1 billion in 2005.3 However, the increase
in funding has not been accompanied by a rise in the
number of new drugs approved by the US Food and
Drug Administration (FDA). The number of approvals
for all neuroscience drugs and for new molecular enti-
ties, compounds that contain an active ingredient that
has never been marketed in the United States, has
largely been stagnant over the last decade1,3 and has
raised questions about the productivity of biomedical
research.3–5 The recent constraints on National Insti-
tutes of Health (NIH) funding of biomedical research6
and cutbacks within the pharmaceutical industry7 all
heighten concerns about prospects for growth in fund-
ing for biomedical research. Against this backdrop, the
need to allocate resources efﬁciently and effectively
will likely grow.
Parkinson disease (PD) is the second most common
neurodegenerative condition whose US and global bur-
den will grow over the next generation.8 Since 1995,
at least 10 new drugs (pramipexole, ropinirole, tolca-
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pone, entacapone, apomorphine, rasagiline, selegiline,
carbidopa/levodopa/entacapone, selegiline sublingual,
and rotigotine) have been approved in the United
States for an indication related to PD.3,9–12 These drugs
have beneﬁted people with PD, but most of the gain
has been incremental with critiques focusing on their
‘‘diminishing therapeutic returns.’’13 To help address
the need to maximize the value of resources devoted to
PD, we sought to determine the level and principal
sources of recent funding for PD research and to deter-
mine the current state of PD drug development.
METHODS
Therapeutic Pipeline for PD
We used a proprietary database (Pharmaprojects)14
to identify therapies in development for PD for 2003
through 2007. Pharmaprojects contains data on more
than 7,000 drug candidates in active development,
including target indication, progress to date, and com-
mercial history of the compound and is commonly
used by industry, ﬁnancial services ﬁrms, and research-
ers to track drug development. We identiﬁed com-
pounds (small molecules and biologics) in development
for PD as having a therapy description of ‘‘antiparkin-
sonian.’’ We also included stem cell and gene therapies
that had antiparkinsonian listed as an indication. We
then excluded compounds from the list with ‘‘primary
therapy’’ and ‘‘primary pharmacology’’ descriptions
that were inconsistent with compounds targeted for PD
(e.g., treatments for multiple sclerosis). We restricted
our analysis to those compounds that were in develop-
ment from the preclinical stage to phase III. One com-
pound listed only as ‘‘clinical trial’’ was assumed to be
in phase I. The years for which the drug development
status was missing were ﬁlled using the development
status from the prior years (n 5 7 compounds).
For each compound in development, we identiﬁed
the company that was listed as its ‘‘originator.’’ Each
company’s home country was identiﬁed from the Phar-
maprojects database. Revenue for ﬁscal year 2007 was
obtained from publicly available information on the
US Securities and Exchange Commission website
(forms 10-K or 20-F) (n 5 24),15 annual reports on
company websites (n 5 27), or Hoover’s business
database (n 5 18).16 If a ﬁrm was owned by a parent
company, revenues from the parent company were
used. Fiscal year 2007 revenues were converted to US
dollars based on the exchange rates17 on March 31,
2007 (end of ﬁscal year when most annual reports
were published).
To assess the progression of drugs in development,
we evaluated the drugs listed in development in Phar-
maprojects in 2003 to see whether they were still in
development in 2007 and whether their phase of devel-
opment had progressed. We used a 4-year lag period
as this length approximates the phase with the longest
duration (39 months for phase II) for neurological drug
development.18 We compared the rate of progression
(likelihood of a drug advancing from one phase to the
next phase, such as from phase II to phase III) to pub-
lished estimates for the likelihood of advancement for
neurological diseases as a whole.18
Funding for PD Research
To estimate the annual research costs associated
with developing each compound, we used published
estimates for research costs for each phase of develop-
ment ($15.2 million for phase I, $23.5 million for
phase II, and $86.3 million for phase III) and adjusted
them to account for the different duration of investiga-
tion (1.8 years for phase I, 2.1 years for phase II, and
2.5 years for phase III) to obtain annual estimates for
research costs at each phase ($8.4 million annual de-
velopment cost for Phase I, $11.0 million for Phase II,
and $34.0 million for Phase III).19,20 We excluded
costs due to long-term animal testing during clinical
development. The annual preclinical research costs
($6.8 million) were estimated using the average costs
from two published studies.19,20 We excluded com-
pounds (n 5 6) that were sponsored by nonproﬁt insti-
tutions, such as the NIH (whose research support was
captured directly) or universities.
For the medical device industry, we identiﬁed the
company with the largest market share for deep brain
stimulation (Medtronic) and allocated its research and
development budget in proportion to its sales of
devices for PD-based on data from its Security and
Exchange Commission ﬁling.21
As part of a larger assessment of the landscape of
funding for PD, we obtained US federal estimates for
research support for PD from 2003 through 2005 from
the NIH and the Department of Defense through a
direct request (Directors of each Institute at the NIH,
Stephen Grate, DOD, personal communication). Some
of these data are available publicly through either web-
sites22 or publicly accessible databases.23 We similarly
solicited such data from four large PD foundations
based in the United States (Parkinson’s Disease Foun-
dation, American Parkinson Disease Association,
National Parkinson Foundation, Michael J. Fox Foun-
dation for Parkinson’s Research) through a direct
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request (Robin Elliott, personal communication; Joel
Gerstel, personal communication, date; Jose Garcia
Pedrosa, personal communication; Deborah Brooks,
personal communication). Importantly, this analysis did
not include support from government and foundation
sources outside the United States.
RESULTS
Funding for PD research from industry worldwide,
the US federal government, and US-based foundations
grew from $1.1 billion in 2003 to $1.2 billion in 2005
(Table 1). Of the sources examined, industry was the
largest sponsor, accounting for 77% of total funding
from 2003 to 2005. Funding from US-based founda-
tions increased from $15 million in 2003 to $20 mil-
lion in 2005.
The number of compounds in the PD development
pipeline increased from 67 in 2003 to 97 in 2007 (Fig.
1). The growth was largely due to an increase in the
number of preclinical compounds, which increased by
65% and comprised the majority (63%) of compounds
in development in 2007.
The number of companies developing compounds
for PD increased from 53 in 2003 to 80 in 2007, with
no company sponsoring more than three different com-
pounds. Fifty-nine (74%) of the 80 companies entered
the market between 2003 and 2007. Financial informa-
tion was available for 69 (86%) of the 80 companies.
As measured by 2007 revenue, most of the companies
with compounds in development were small (Fig. 2).
Forty-seven percent had revenue of less than $10 mil-
lion and an additional 15% had revenue between $10
and $100 million. More than half (53%) of the compa-
nies with at least one compound in development in
2007 were based outside the United States (Fig. 3).
Of the 67 compounds in development in 2003, 13
compounds had advanced in development by 2007
TABLE 1. Funding for Parkinson disease research, 2003 to
2005 (in millions of US dollars)
Source 2003 2004 2005
US-based foundations $15 $22 $20
US Federal Government* $261 $224 $236
Industry $785 $882 $948
Total $1,061 $1,128 $1,204
*Includes the US National Institutes of Health and the Department
of Defense.
FIG. 1. Number of compounds in development for Parkinson disease
by phase of development, 2003–2007.
FIG. 2. Size of companies with at least one compound in develop-
ment for Parkinson disease in 2007 by ﬁscal year 2007 revenue.
100% 5 80 companies.
FIG. 3. Companies with at least one compound in development for
Parkinson disease in 2007 by country. 100% 5 80 companies. [Color
ﬁgure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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(Table 2). An additional eight compounds remained in
the same stage of development and may yet advance.
The proportion of drugs advancing to the next phase of
development varied from state to stage. Three (8%) of
the 37 preclinical compounds in development in 2003
had advanced into clinical development by 2007. Four
(50%) of the eight compounds in Phase III in 2003
had advanced to market entry by 2007.
DISCUSSION
Funding for PD research from industry and US-
based foundations and the US federal government
exceeds $1 billion annually. As is the case for biomed-
ical and neuroscience research generally, industry
rather than the US federal government is the principal
sponsor of PD research and development. However,
most of this research support is not from large pharma-
ceutical companies, as is the case for biomedical
research as a whole1 or neuroscience generally.3 Less
than 20% of the companies with compounds in devel-
opment for PD had revenue exceeding a billion dollars,
an amount typically associated with sales of a single
‘‘blockbuster’’ drug. This research support is coming
from small, in some cases very small, privately held
biotechnology ﬁrms—more than half of which are
located outside the United States.
Smaller companies are unlikely to have the scale,
resources, or expertise to drive the development of
therapeutics for PD alone and consequently have high
turnover, which may impede the overall development
of new therapies. Generally, companies with less expe-
rience in developing drugs have lower rates of success
for advancing a drug through each phase of develop-
ment.24 Smaller companies often license out com-
pounds to larger companies as the compounds progress
through drug development;24 however, the limited data
on licensees available in Pharmaprojects suggests that
only nine of the 36 compounds in clinical development
(phase I through phase III) for PD in 2007 had been
licensed to another company. The emergence of the
role of smaller companies in drug development likely
reﬂects the relative shift of large pharmaceutical
research expenditures away from pre-clinical research.
From 1994 to 2003, the proportion of large pharmaceu-
tical research and development expenditures that went
to preclinical research fell from 57 to 32%.1 In its
place, large pharmaceutical companies shifted their
expenditures to clinical and post-marketing studies,
which rose from 5% of expenditures to 11% over the
same time period.1
Drug development is costly, long, and risky. To de-
velop a drug once it enters clinical trials (Phase I)
costs between $500 million to more than $2 billion
and takes 7 to 8 years.18 To our knowledge, no pub-
lished data on costs and time to develop drugs speciﬁc
for PD is available. However, published reports indi-
cate that the clinical development of drugs with an
Alzheimer disease indication takes 72 months when
compared with 93 months for rheumatoid arthritis and
63 months for HIV/AIDS.18 Drug development is also
uncertain. The probability of a drug successfully enter-
ing the next phase of development varies considerably
by therapeutic area. For example, the likelihood of a
drug successfully completing Phase II and entering
Phase III ranges from 31 to 67%.18 In this study, the
advancement rate of drugs in development for PD was
quite variable (likely due in part to the small sample
size) compared to published estimates for all neurolo-
gical diseases (Table 2).
For symptomatic treatment, models for PD are well-
developed and the regulatory pathway is clear as evi-
denced by the large number of recently approved treat-
ments for PD. For disease modifying treatments, the
path is less clear25 and faces several challenges,
including the lack of a reliable animal model to predict
clinical response in humans, the absence of biomarkers
that correlate well with clinical measures, and the
subjectivity of endpoints commonly used in PD trials.
The lack of an animal model with predictive validity
for neuroprotective/disease modifying therapies has
resulted in several compounds that have demonstrated




in development in 2003
Number that had advanced
in development by 2007
Percent that had advanced
in development by 2007
Likelihood of advancement for
neurological drugs as a whole18
Preclinical 37 3 8% NA
Phase I 8 3 38% 73%
Phase II 14 3 21% 41%
Phase III 8 4 50% 22%
Total 67 13 19% NA
NA, Not Available.
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success in pre-clinical models but have failed clini-
cally.26,27 In the absence of a preclinical tool that can
be used to predict the efﬁcacy of a putative therapy,
pharmaceutical and clinical investigators face addi-
tional uncertainty in deciding whether to advance a
therapy into expensive clinical trials.26
Without reliable animal models, biomarkers can be
especially helpful in screening promising compounds.
However, the PD ﬁeld does not currently have such
markers.28 Imaging modalities to date have shown util-
ity in differentiating those with a dopaminergic deﬁcit
versus those without but have not shown utility in
demonstrating improvement that correlates with clini-
cal measures.29,30 Peripheral biomarkers that reﬂect
drug activity or provide evidence of a drug’s mecha-
nism of action are also largely missing in PD as are
markers that can assess a drug’s penetration of the
blood brain barrier.
The lack of valuable biomarkers in PD increases the
importance of the clinical endpoints used in PD.
Unfortunately, many endpoints currently used (e.g.,
patient diaries) are subjective although efforts are
underway to improve them.31 The absence of objective
endpoints in clinical trials may lead to higher failure
rates.32 In addition, because of its course, PD often
requires clinical trials with long durations. Perhaps
reﬂecting the progressive nature of many neurological
conditions, drug development costs are higher and du-
ration longer for neurological disorders than for infec-
tious diseases, for example.18
To meet these challenges and to address the limited
resources and capabilities of smaller companies, addi-
tional partnerships with academia, governments, large
pharmaceutical ﬁrms, foundations, and other entities
will likely be required to drive the development of PD
therapies. Novel models for collaboration among
industry, academia, foundations, and government exist.
Among them are the Myelin Repair Foundation, which
has a unique business/science model narrowly focused
on developing new treatments for multiple sclerosis
rapidly, and the Alzheimer’s Disease Neuroimaging
Initiative, the largest NIH–private partnership in brain
research that involves NIH, FDA, and several founda-
tions and pharmaceutical companies with a common
aim of developing imaging biomarkers to measure cog-
nitive decline.33 Abroad, large pharmaceutical compa-
nies, such as GlaxoSmithKline, have formed partner-
ships with government funders and academic institu-
tions, such as University College London, to identify
and develop treatments for Creutzfeldt-Jacob disease.33
Foundations, with their ability to overcome traditional
barriers and strike alliances among universities, investi-
gators, and companies, may play an especially impor-
tant role.34 In PD, foundations have begun recognizing
the limitations of some of the smaller companies driv-
ing PD drug development and have programs in place
to support these companies.35 Additionally, broader
efforts that more closely join smaller companies and
their compounds, investigators and their expertise, and
foundations and their resources and ability to bring in
additional partners (e.g., large pharmaceutical compa-
nies, public funders, private individuals) may catalyze
future progress in developing treatments for PD. In
particular, PD may beneﬁt from alliances and invest-
ment aimed at validation of drug discovery and devel-
opment tools, such as biomarkers, in vitro validation
techniques, and small proof of principle clinical trials.
This study was limited by data constraints because
only limited information is available publicly. Our
analysis only included US federal (NIH and Depart-
ment of Defense) and foundation support while the
analysis of industry support extended abroad. The esti-
mates for the ﬁnancing of PD research excluded many
additional sponsors, including government and founda-
tion support outside the United States, other US federal
and state agencies, universities, private organizations,
and individuals. However, the largest US funders of
biomedical research1 (industry and NIH) were included
in the study. The funding data were also limited by the
absence of actual industry data on research and devel-
opment support for PD. We, therefore, estimated
research support based on published estimates of the
average annual cost of supporting a compound at each
stage of development because most companies, even
many large ones, do not report research and develop-
ment expenditures by disease area. The data on com-
pounds in development for PD is also likely incom-
plete. The database (Pharmaprojects) that we used
relies on multiple sources (e.g., public ﬁlings, press
releases, conference presentations) but is neither per-
fect nor exhaustive. For example, Pharmaprojects’ des-
ignation of compounds in development as anti-parkin-
sonian may not be accurate (e.g., drug is actually in
development for an indication other than PD). In addi-
tion, early stage compounds, especially at large phar-
maceutical companies, may not be readily identiﬁed
and thus may be underrepresented in the database. The
limitations on the identiﬁcation of compounds also
carry over to estimates on industry support for PD
research. For example, to the extent that pre-clinical
compounds are not captured by Pharmaprojects, indus-
try support will be underestimated. Finally, data on
licensing of compounds to large pharmaceutical com-
panies is likely incomplete and may not always be
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current. Despite its limitations, the database is exten-
sive and widely used by economists,36 industry
experts,32 and government agencies18 examining drug
development.
The therapeutic pipeline, especially preclinical com-
pounds, for PD is growing, and the development of
these therapies rests in the hands of small companies
with limited resources. Global partnerships that capital-
ize on the expertise of investigators, the resources of
government and foundations, and the active participa-
tion of patients will likely be required to foster the suc-
cessful development of new treatments for PD.
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